Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

To improve treatment efficacy, we decided to simultaneously target HER1 and HER2 with trastuzumab and cetuximab. Following promising preclinical results, we conducted a phase 1-2 trial in advanced pancreatic cancer patients after first-line gemcitabine-based chemotherapy failure. In this single-arm,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Assenat, Eric, Azria, David, Mollevi, Caroline, Guimbaud, Rosine, Tubiana-Mathieu, Nicole, Smith, Denis, Delord, Jean-Pierre, Samalin, Emmanuelle, Portales, Fabienne, Larbouret, Christel, Robert, Bruno, Bibeau, Frédéric, Bleuse, Jean-Pierre, Crapez, Evelyne, Ychou, Marc, Pèlegrin, André
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494975/
https://ncbi.nlm.nih.gov/pubmed/25918250
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars